Development of a Foot-and-Mouth Disease Infection Model in Severe Combined Immunodeficient Mice for the Preliminary Evaluation of Antiviral Drugs

Transboundary and Emerging Diseases

Volumn 57, Issue 6, 2010, Pages 430-433

  Lefebvre, D J ^a   Neyts, J ^b   De Clercq, K ^a  

^a VETERINARY AND AGROCHEMICAL RESEARCH CENTRE   (Belgium)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Antiviral drugs; Foot and mouth disease; Foot and mouth disease virus; Lead optimization phase; Severe combined immunodeficient mice

Indexed keywords

ANTIVIRUS AGENT;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CLASSIFICATION; DISEASE MODEL; DRUG EFFECT; FEMALE; FOOT AND MOUTH DISEASE; FOOT AND MOUTH DISEASE VIRUS; IMMUNOCOMPROMISED PATIENT; MALE; MORTALITY; MOUSE; STANDARD;

ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; FEMALE; FOOT-AND-MOUTH DISEASE; FOOT-AND-MOUTH DISEASE VIRUS; IMMUNOCOMPROMISED HOST; MALE; MICE; MICE, INBRED BALB C;

ANIMALIA; FOOT-AND-MOUTH DISEASE VIRUS; MUS; RODENTIA;

EID: 78449247859     PISSN: 18651674     EISSN: 18651682     Source Type: Journal    
DOI: 10.1111/j.1865-1682.2010.01169.x     Document Type: Article

References (10)

1. Golde, W. T., J. M. Pacheco, H. Duque, T. Doel, B. Penfold, G. S. Ferman, D. R. Gregg, and L. L. Rodriguez, 2005: Vaccination against foot-and-mouth disease virus confers complete clinical protection in 7 days and partial protection in 4 days: use in emergency outbreak response. Vaccine 23, 5775-5782.
2. Goris, N., A. De Palma, J. F. Toussaint, I. Musch, J. Neyts, and K. De Clercq, 2007: 2'-C-methylcytidine as a potent and selective inhibitor of the replication of foot-and-mouth disease virus. Antiviral Res. 73, 161-168.
3. Goris, N., F. Vandenbussche, and K. De Clercq, 2008: Potential of antiviral therapy and prophylaxis for controlling RNA viral infections of livestock. Antiviral Res. 78, 170-178.
4. Goris, N., F. Vandenbussche, C. Herr, J. Villers, Y. Van der Stede, and K. De Clercq, 2009: Validation of two real-time RT-PCR methods for foot-and-mouth disease diagnosis: RNA-extraction, matrix effect, uncertainty of measurement and precision. J. Virol. Methods 160, 157-162.
5. Grubman, M. J., and B. Baxt, 2004: Foot-and-mouth disease. Clin. Microbiol. Rev. 17, 465-493.
6. Kamstrup, S., T. H. Frimann, and A. M. Barfoed, 2006: Protection of Balb/c mice against infection with FMDV by immunostimulation with CpG oligonucleotides. Antiviral Res. 72, 42-48.
7. NIAID, The National Institute of Allergy and Infectious Diseases, 2010: Antimicrobial acquisition and coordinating facility AACF, animal models of human viral infections for evaluation of experimental therapeutics. Available at (accessed June 3, 2010).
8. OIE, World Organisation for Animal Health, 2010: Handistatus II. EUROPE/2001/Foot and mouth disease, animal health status. Available at (accessed June 3, 2010).
9. Paton, D. J., J.-F. Valarcher, I. Bergmann, O. G. Matlho, V. M. Zakharov, E. L. Palma, and G. R. Thomson, 2005: Selection of foot and mouth disease vaccine strains - a review. Rev. Sci. Tech. Off. Int. Epiz. 24, 981-994.
10. Salguero, F. J., M. A. Sánchez-Martín, F. Díaz-San Segundo, A. De Avila, and N. Sevilla, 2005: Foot-and-mouth disease virus (FMDV) causes an acute disease that can be lethal for adult laboratory mice. Virology 332, 384-396.